Tony Weisman was appointed Director of Ibotta, Inc. As of November 6, 2026, Ibotta, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 24, 2026, naming 2 appointments and 1 departure (Form 8-K, September 24, 2026).
Ibotta, Inc. named a new Director on Sep 24. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Ibotta, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Tony Weisman · Role: Director · 8-K, 2026-09-24
- · In / out: In · Person: Tony Weisman · 8-K, 2026-09-24
- · In / out: Out · Person: Thomas Lehrman · Role: Director · 8-K, 2026-09-24
Ibotta, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-24. It names 2 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Ibotta, Inc. files it.
Also on the record for Ibotta, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G, by KDT Ibotta Holdings, LLC | 18% of the class | 5%+ stakes | Source |
| April 2, 2026 | Stake report, Schedule 13D, by KDT Ibotta Holdings, LLC | 20.7% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by D. E. Shaw & Co., L.P. | 7.2% of the class | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Amova Asset Management Americas, Inc. | 1.5% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by Sumitomo Mitsui Trust Group, Inc. | 1.5% of the class | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | 4.96% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G, by Amova Asset Management Americas, Inc. | 5.1% of the class | 5%+ stakes | Source |
| October 27, 2025 | Stake report, Schedule 13G, by Sumitomo Mitsui Trust Group, Inc. | 5.1% of the class | 5%+ stakes | Source |
| September 12, 2025 | Stake report, Schedule 13G, by Clark Jermoluk Founders Fund I LLC | 15.2% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G, by Southpoint Master Fund, LP | 1.1% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by D. E. Shaw & Co., L.P. | 5.7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Ibotta, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Ibotta, Inc. and the records around it.
Ibotta, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Southpoint Master Fund, LP also filed stake reports on 2 other companies: Dentsply Sirona Inc. (Aug 2026), Fennec Pharmaceuticals Inc. (Aug 2026)
- Amova Asset Management Americas, Inc. also filed stake reports on 3 other companies: 10x Genomics, Inc. (Nov 2025), Arcturus Therapeutics Holdings Inc. (Nov 2025)
- Sumitomo Mitsui Trust Group, Inc. also filed stake reports on 7 other companies: Arcturus Therapeutics Holdings Inc. (Oct 2026), GCM Grosvenor Inc. (Apr 2026), 10x Genomics, Inc. (Oct 2025)
Watch Ibotta, Inc.
Get an email when Ibotta, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Ibotta, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Ibotta, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ibotta, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-24 | In | Director | 8-K, 2026-09-24 | ||
| 2026-09-24 | In | 8-K, 2026-09-24 | |||
| 2026-09-24 | Out | Director | 8-K, 2026-09-24 |
Who leads Ibotta, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Tony Weisman, appointed (filed 2026-09-24).
New leaders reset buying decisions — get the Full Report on Ibotta, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Ibotta, Inc., with the record behind each one.
Find candidates like Director at Ibotta, Inc.Every change, in the filing's words
Appointed: Tony Weisman, Director
Director Appointment On September 22, 2026, (the "Effective Date"), the board of directors (the "Board") of Ibotta, Inc. (the "Company"), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Tony Weisman to serve as a Class I director effective as of the Effective Date, with an initial term expiring at the Company's 2028 annual meeting of shareholders.
Appointed: Tony Weisman
As of the Effective Date, the Board also appointed Mr. Weisman as a member of the Company's Audit Committee.
Departing: Thomas Lehrman, Director
Director Resignation On September 22, 2026, Thomas Lehrman, a member of the Board, notified the Company of his resignation from the Board and all committees thereof, effective immediately.
- Mr. Weisman will participate in the Company's outside director compensation policy, as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 7, 2026.
- In addition, the Company entered into its standard form of indemnification agreement with Mr. Weisman.
- The Company is not aware of any disagreement between Mr. Lehrman and the Company on any matter relating to the Company's operations, policies, or practices that resulted in Mr. Lehrman's resignation.
Tools for this story
Each opens in a new tab, filled in for Ibotta, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.